New study identifies biomarkers for early risk assessment of acute kidney injury

Acute kidney injury strikes large numbers of hospitalized patients, including those with no prior kidney-related illness, and is one of the most costly and deadly conditions affecting critically ill patients. Findings published today in Critical Care from a Mayo Clinic-led, multicenter study identify two biomarkers of acute kidney injury that can be easily measured in urine and detect affected patients roughly 12 to 36 hours earlier than current tests.

"Failure to recognize and manage acute kidney injury in the early stages can lead to devastating outcomes for patients and increased costs to the . Unfortunately, current blood and urine tests are not able to detect it early enough to avoid further complications or provide any chance for intervention," says lead author Kianoush B. Kashani, M.D., a and intensivist at Mayo Clinic.

The study's findings give physicians a tool to determine early on whether a patient is at risk, Dr. Kashani says.

Researchers evaluated nearly 340 biomarkers to find the two with the highest correlation to kidney injury risk. The markers, Insulin Growth Factor -7 (IGFBP-7) and Tissue Inhibitor of Metalloproteinases-2 (TIMP-2), were later validated by another multicenter study known as the Sapphire Trial.

add to favorites email to friend print save as pdf

Related Stories

Warning signs predict kidney injury after surgery

Aug 12, 2011

Acute kidney injury (AKI) is a common – but preventable -- complication after surgery that can lead to other complications or even death. The use and development of biomarkers will help physicians diagnose and treat ...

Recommended for you

Asthma drug may help those with chronic hives

13 hours ago

(HealthDay)—A drug already used to treat moderate-to-severe allergic asthma appears to offer relief to people with chronic hives who haven't been helped by standard medications, new research suggests.

User comments